AI English summary of an SEC filing — figures as filed
ResMed RMDThe company said revenue for the 3-month period ended March 31, 2025 was $1,291.7 million, up 8% from $1,197.0 million a year earlier, and up 9% on a constant currency basis. Income from operations was $426.3 million, up 14%, and non-GAAP income from operations was $444.6 million, up 13%.
Key points
AI summaryThe company said revenue for the 3-month period ended March 31, 2025 was $1,291.7 million, up 8% from $1,197.0 million a year earlier, and up 9% on a constant currency basis. Income from operations was $426.3 million, up 14%, and non-GAAP income from operations was $444.6 million, up 13%.
ResMed said gross margin for the quarter was 59.3%, improved by 140 basis points, and non-GAAP gross margin was 59.9%. The company cited manufacturing and logistics efficiencies and shifts in product mix as factors in the gross margin change. Net income was $365.0 million, diluted earnings per share was $2.48, and non-GAAP diluted earnings per share was $2.37.
The company said operating cash flow for the quarter was $579 million. It received $107 million in tax refunds from the IRS during the quarter, and it said operating cash flow excluding those refunds was $471 million.
ResMed said its board declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025 and a payment date of June 12, 2025. The company said it paid $78 million in dividends during the quarter and repurchased 314,000 shares for $75 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Revenue and operating income for the quarter ended March 31, 2025
The company said revenue for the 3-month period ended March 31, 2025 was $1,291.7 million, up 8% from $1,197.0 million a year earlier, and up 9% on a constant currency basis. Income from operations was $426.3 million, up 14%, and non-GAAP income from operations was $444.6 million, up 13%.
Source · Based on the filing body and exhibits
Gross margin, net income and EPS
ResMed said gross margin for the quarter was 59.3%, improved by 140 basis points, and non-GAAP gross margin was 59.9%. The company cited manufacturing and logistics efficiencies and shifts in product mix as factors in the gross margin change. Net income was $365.0 million, diluted earnings per share was $2.48, and non-GAAP diluted earnings per share was $2.37.
Source · Based on the filing body and exhibits
Quarterly operating cash flow and tax refunds
The company said operating cash flow for the quarter was $579 million. It received $107 million in tax refunds from the IRS during the quarter, and it said operating cash flow excluding those refunds was $471 million.
Source · Based on the filing body and exhibits
Dividend declaration and quarterly shareholder returns
ResMed said its board declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025 and a payment date of June 12, 2025. The company said it paid $78 million in dividends during the quarter and repurchased 314,000 shares for $75 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…